Fidelity
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 61
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
Long View On Stocks Is Best During Weak Earnings Season
Taking the long-term view is probably the best course of action for investors given the weakness of first-quarter results as we head into the peak week of first-quarter earnings season with reports from heavyweights like Apple Inc., Microsoft Corp., and AT&T Inc.
Client Balances at Morgan Stanley Wealth Management Near Merrill Lynch
Citi Picks Dewilde to Lead Asia Markets and Investor Services Business
U.S. Hot Stocks: Hot Stocks to Watch
IBM's Profit Slides As Hardware Sales Keep Falling
SanDisk, Weibo Gains Pace Tech Stocks
Fast-Rising Costs Erode Google's Profits -- 3rd Update
European Stocks Turn Higher, But Rémy, Diageo Lag
Yahoo CEO Mayer's Compensation Falls
FCC to Set Aside Spectrum for Smaller Wireless Carriers
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 177022 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist